ArticleCureus2022
Propylthiouracil-Induced Skin Vasculitis.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 4 citations in OpenAlex.
- Propylthiouracil-induced myeloperoxidase antineutrophil cytoplasmic antibody-associated leukocytoclastic vasculitis.JCEM case reports · 2026Article
- A grave complication: propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis.JCEM case reports · 2026Article
- From Thyroid Therapy to Systemic Crisis: PTU-Induced c-ANCA Vasculitis Accompanied by Cold-Agglutinin Disease and Organ Failure.European journal of case reports in internal medicine · 2026Article
- Propylthiouracil-Induced Vasculitis in Relapsed Graves' Disease With Recent Iodine Exposure: A Therapeutic Dilemma.Cureus · 2025Article
- A disproportionality analysis of FDA adverse event reporting system (FAERS) events for methimazole and propylthiouracil.PloS one · 2025Article
- Propylthiouracil-induced vasculitis.Proceedings (Baylor University. Medical Center) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of propylthiouracil (PTU) is associated with the development of autoantibodies, namely, antineutrophil cytoplasmic antibodies (ANCAs), which are associated with the pathogenesis of ANCA-associated systemic vasculitis, most often related to the myeloperoxidase subtype (ANCA-MPO). The authors report the case of a 61-year-old woman on PTU for one year who was referred to Internal Medicine for a three-month evolution of painless non-blanching purple patches, non-pruriginous, involving the chest and legs. The autoimmunity revealed ANCA antibody positivity, with a cutaneous biopsy compatible with leukocytoclastic vasculitis/necrotizing vasculitis with involvement of small and medium-sized vessels. Clinical improvement was noted after the drug was discontinued, with the resolution of the analytical changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.